Inventor · disambiguated record
Steve Pascolo
Also filed as: PASCOLO STEVE
24 granted patents·39 pending applications·679 citations·filing 2003–2022
97Inventor score
Top patents by PatentIndex Score
63 records- 0199US9655955B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted May 23, 2017·42 cites·20 claims
- 0299US9463228B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Oct 11, 2016·28 cites·20 claims
- 0399US9439956B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Sep 13, 2016·29 cites·19 claims
- 0499US9433669B2Application of mRNA for use as a therapeutic against tumor diseasesCUREVAC AG·Filed 2015·Granted Sep 6, 2016·29 cites·20 claims
- 0599US9433670B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC AG·Filed 2015·Granted Sep 6, 2016·29 cites·20 claims
- 0698US11135312B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2014·Granted Oct 5, 2021·35 cites·16 claims
- 0798US10568972B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2016·Granted Feb 25, 2020·35 cites·23 claims
- 0898US9155788B2Application of mRNA for use as a therapeutic against tumour diseasesCUREVAC GMBH·Filed 2014·Granted Oct 13, 2015·64 cites·20 claims
- 0998US8217016B2Application of mRNA for use as a therapeutic agent for tumorous diseasesHOERR INGMAR·Filed 2004·Granted Jul 10, 2012·195 cites·27 claims
- 1097US11661634B2Method for producing RNACUREVAC MFG GMBH·Filed 2022·Granted May 30, 2023·7 cites·30 claims
- 1197US11369691B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsCUREVAC AG·Filed 2016·Granted Jun 28, 2022·11 cites·19 claims
- 1297US11268157B2Method for producing RNACUREVAC REAL ESTATE GMBH·Filed 2020·Granted Mar 8, 2022·29 cites·18 claims
- 1397US10711315B2Method for producing RNACUREVAC REAL ESTATE GMBH·Filed 2018·Granted Jul 14, 2020·28 cites·16 claims
- 1496US10017826B2Method for producing RNACUREVAC AG·Filed 2016·Granted Jul 10, 2018·29 cites·34 claims
- 1595US10188748B2Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regionsVON DER MUELBE FLORIAN·Filed 2003·Granted Jan 29, 2019·72 cites·32 claims
- 1693US11421038B2RNA-coded antibodyHOERR INGMAR·Filed 2008·Granted Aug 23, 2022·12 cites·31 claims
- 1787US10980875B2Cytotoxic immunostimulating particles and uses thereofBIONTECH AG·Filed 2016·Granted Apr 20, 2021·2 cites·13 claims
- 1885US2022372158A1Rna-coded antibodyCUREVAC AG·Filed 2022·Application pending·0 cites
- 1979US10172960B2Particles comprising single stranded RNA and double stranded RNA for immunomodulationBIONTECH AG·Filed 2017·Granted Jan 8, 2019·1 cites·11 claims
- 2079US2022154253A1Method for producing rnaCUREVAC REAL ESTATE GMBH·Filed 2022·Application pending·0 cites
- 2174US10646576B2Immunostimulating-toxic RNA in alkaline earth metal formulationSPRNA GMBH·Filed 2016·Granted May 12, 2020·1 cites·26 claims
- 2273US9636414B2Particles comprising single stranded RNA and double stranded RNA for immunomodulationPASCOLO STEVE·Filed 2011·Granted May 2, 2017·1 cites·23 claims
- 2373US2019284260A1Rna-coded antibodyCUREVAC AG·Filed 2019·Application pending·0 cites
- 2470US12263215B2Cytotoxic immunostimulating particles and uses thereofBioNTech SE·Filed 2021·Granted Apr 1, 2025·0 cites·19 claims
- 2570US2019134222A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC AG·Filed 2018·Application pending·0 cites
- 2670US2022347308A1Methods and means for inducing an immune responseBIONTECH AG·Filed 2022·Application pending·0 cites
- 2769US2021308238A1Injection solution for rnaCUREVAC AG·Filed 2021·Application pending·0 cites
- 2867US2023181765A2PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCureVac SE·Filed 2016·Application pending·0 cites
- 2966US2017211068A1Immunostimulation by chemically modified rnaCUREVAC AG·Filed 2017·Application pending·0 cites
- 3065US2013195867A1Rna-coded antibodyCUREVAC GMBH·Filed 2012·Application pending·0 cites
- 3164US2016152691A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3264US2016145346A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3364US2016166692A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3464US2016166690A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3564US2016152706A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3664US2016361438A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC AG·Filed 2016·Application pending·0 cites
- 3764US2016185840A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3864US2016166691A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 3964US2016168254A1Rna-coded antibodyCUREVAC AG·Filed 2016·Application pending·0 cites
- 4063US2008025944A1Combination Therapy for ImmunostimulationCURE VAC GMBH·Filed 2005·Application pending·0 cites
- 4163US2013273001A1Immunostimulation by chemically modified rnaCUREVAC GMBH·Filed 2013·Application pending·0 cites
- 4263US2011123637A1Protamine/rna nanoparticles for immunostimulationUNIV ZUERICH·Filed 2009·Application pending·0 cites
- 4361US2011269950A1PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONSCUREVAC GMBH·Filed 2011·Application pending·0 cites
- 4460US10626400B2Stabilised formulations of RNABIONTECH AG·Filed 2014·Granted Apr 21, 2020·0 cites·10 claims
- 4560US2017000870A1Combination therapy for immunostimulationCUREVAC AG·Filed 2016·Application pending·0 cites
- 4660US2012213818A1Combination therapy for immunostimulationHOERR INGMAR·Filed 2012·Application pending·0 cites
- 4759US9771594B2Pharmaceutical composition consisting of RNA having alkali metal as counter ion and formulated with dicationsPASCOLO STEVE·Filed 2013·Granted Sep 26, 2017·0 cites·29 claims
- 4859US2005250723A1Immunostimulation by chemically modified RNAHOERR INGMAR·Filed 2004·Application pending·0 cites
- 4958US2011311472A1Application of mrna for use as a therapeutic against tumour diseasesHOERR INGMAR·Filed 2011·Application pending·0 cites
- 5058US2011077287A1Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regionsCUREVAC GMBH·Filed 2010·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Steve Pascolo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →